(PharmaNewsWire.Com, August 26, 2017 ) Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Candidiasis - Pipeline Review, H2 2017”. Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash.
It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 7, 2, 22, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.
Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Candidiasis - Overview 7 Candidiasis - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 Candidiasis - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Candidiasis - Companies Involved in Therapeutics Development 25 Amplyx Pharmaceuticals Inc 25 Bakker Medical Srl 25 Beta Pharma Inc 26 Biomar Microbial Technologies 26 Bionex Pharmaceuticals LLC 27 Biosergen AS 27 Cidara Therapeutics Inc 28 Dermala Inc 28 Gedea Biotech AB 29 General Biologicals Corp 29 Grupo Ferrer Internacional SA 30 Hsiri Therapeutics LLC 30 iCo Therapeutics Inc. 31 ImmunoClin Corp 31 Matinas BioPharma Holdings Inc 32 Nanomerics Ltd 32 Novabiotics Ltd 33 NovaDigm Therapeutics Inc 33 Novartis AG 34 Onxeo SA 34 Scynexis Inc 35 Sealife PHARMA GMBH 35 Viamet Pharmaceuticals Inc 36 Visterra Inc 36 Wellstat Vaccines LLC 37 Candidiasis - Drug Profiles 38 (clotrimazole + diclofenac sodium) - Drug Profile 38 61894700 - Drug Profile 39 AC-17 - Drug Profile 40 amphotericin B - Drug Profile 41 amphotericin B - Drug Profile 43 amphotericin B - Drug Profile 49 Amphotericin B sodium - Drug Profile 50 Antibody to Target Ece1 for Candidiasis - Drug Profile 52 APX-001 - Drug Profile 53 APX-001A - Drug Profile 55 arasertaconazole - Drug Profile 56 B-4010 - Drug Profile 57 BL-5923 - Drug Profile 58 BSG-005 - Drug Profile 59
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
